TD Asset Management Inc Sells 185,778 Shares of Boston Scientific Corporation $BSX

TD Asset Management Inc reduced its position in shares of Boston Scientific Corporation (NYSE:BSX) by 8.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,994,416 shares of the medical equipment provider’s stock after selling 185,778 shares during the period. TD Asset Management Inc’s holdings in Boston Scientific were worth $194,715,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Gerber Kawasaki Wealth & Investment Management boosted its position in Boston Scientific by 3.8% during the 2nd quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider’s stock worth $291,000 after acquiring an additional 99 shares during the last quarter. Crown Wealth Group LLC lifted its position in shares of Boston Scientific by 4.7% in the third quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider’s stock worth $218,000 after purchasing an additional 100 shares in the last quarter. Sound View Wealth Advisors Group LLC boosted its holdings in Boston Scientific by 3.9% during the second quarter. Sound View Wealth Advisors Group LLC now owns 2,738 shares of the medical equipment provider’s stock worth $294,000 after purchasing an additional 103 shares during the last quarter. Cary Street Partners Investment Advisory LLC grew its position in Boston Scientific by 5.1% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock valued at $206,000 after purchasing an additional 103 shares in the last quarter. Finally, Scotia Capital Inc. increased its stake in Boston Scientific by 0.7% in the 2nd quarter. Scotia Capital Inc. now owns 15,093 shares of the medical equipment provider’s stock valued at $1,621,000 after buying an additional 104 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Wells Fargo & Company cut their price target on shares of Boston Scientific from $125.00 to $94.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Citigroup reduced their price target on Boston Scientific from $130.00 to $102.00 and set a “buy” rating for the company in a research report on Thursday, February 5th. Needham & Company LLC decreased their price target on Boston Scientific from $121.00 to $97.00 and set a “buy” rating for the company in a research note on Thursday, February 5th. Oppenheimer dropped their price objective on Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a research note on Friday, January 16th. Finally, Truist Financial cut their price objective on Boston Scientific from $120.00 to $95.00 and set a “buy” rating for the company in a report on Thursday, February 5th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $108.36.

Insider Activity

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at $2,396,580. This represents a 42.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the sale, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Stock Performance

Shares of NYSE BSX opened at $73.60 on Thursday. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. Boston Scientific Corporation has a 12 month low of $72.69 and a 12 month high of $109.50. The stock has a 50 day moving average of $88.10 and a 200-day moving average of $95.97. The company has a market capitalization of $109.22 billion, a P/E ratio of 37.94, a P/E/G ratio of 1.04 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same period in the previous year, the firm earned $0.70 EPS. The firm’s revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, equities research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.